Out-patient triple chronotherapy for the rapid treatment and maintenance of response in depression: feasibility and pilot randomised controlled trial

David Veale, Marc Serfaty, Clara Humpston, Andriani Papageorgiou, Sarah Markham, John Hodsoll and Allan H. Young

Background
Triple chronotherapy (sleep deprivation for 36 h, followed by 4 days of advancing the time of sleep and daily morning bright-light therapy for 6 months) has demonstrated benefits for the rapid treatment of depressive symptoms in four small controlled trials of in-patients.

Aims
To test the feasibility of recruitment and delivery of triple chronotherapy for out-patients with depression (ISRCTN17706836; NCT03405493).

Method
In a single-blind trial, 82 participants were randomised to triple chronotherapy or a control intervention. The primary outcome was the number of participants recruited per month and adherence to the protocol. Secondary outcomes included the 6-item Hamilton Rating Scale for Depression (HRSD-6) at 1 week. Timings of observer ratings were baseline and 1, 2, 4, 8 and 26 weeks after randomisation.

Results
The triple chronotherapy group stayed awake for the planned 36 h and 89.9% adhered to the plan of phase advance of their sleep over the following 4 days. We achieved our recruitment target (60 participants completed the trial within 13 months). There were no reported adverse side-effects. We found a significant difference between the groups by intention-to-treat analysis for the HRSD-6 at weeks 1, 8 and 26. There was a large effect size of Cohen’s $d = 0.8$ on HRSD-6 score at week 1, increasing to $d = 1.30$ at week 26. A response (≥50% reduction in symptoms) was achieved by 33.3% in the triple chronotherapy group and 16.2% in the control group. This stayed relatively steady until week 26 (35.9% v. 13.9%).

Conclusions
Triple chronotherapy produced a significant and rapid benefit after 1 week in out-patients with depression that was sustained at 26 weeks. Cost-effectiveness trials with a larger clinical sample are required.

Keywords
Depressive disorders; randomised controlled trial; out-patient treatment; outcome studies; rehabilitation.

Copyright and usage
© The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

There are many treatments for depression with modest efficacy and there is much need and scope for improvement. The effect size for antidepressants against placebo derived from meta-analyses is approximately Cohen’s $d = 0.3$ at 8 weeks1,2 and for cognitive–behavioural therapy the effect size is $d = 0.4$ at 12 weeks.3 However, an identified problem is that the earliest response (defined as 50% reduction in symptoms) for an established treatment of depression such as antidepressant medication4 or a psychological therapy5 may not occur for at least 4–6 weeks. One of the most rapid antidepressants known since the 1970s is a night of total sleep deprivation.4 A meta-analysis of 9 randomised controlled trials (RCTs) and 26 case series on total sleep deprivation for depression found that about 50% of patients recovered within 24 h.5 However, of those who recovered, about 85% relapsed following a night’s sleep, with a diminishing effect if naps were taken during the period of sleep deprivation.6-8 Triple chronotherapy has been developed to sustain this rapid response through administering total sleep deprivation for 36 h, followed by 4 days of advancing the time of sleep, together with daily morning bright-light therapy for 6 months. The rationale is that depression (in some individuals) is associated with circadian rhythm disturbances.7,8 The theory is that triple chronotherapy resynchronises the circadian rhythms, possibly by acting through multisystem mechanisms by regulating neurotransmitters and hormones.7 D’Agostino et al9 published a narrative review and Humpston et al9,10 conducted a meta-analysis of four RCTs (range $n = 14–75$ patients) and 12 case series ($n = 504$ patients) of triple chronotherapy for both unipolar and bipolar depression, almost entirely in in-patients. This showed that for RCTs, triple chronotherapy was favoured at 1 week (Hedge’s $g = 0.62$) and at 8 weeks ($g = 0.35$) compared with active control treatments such as antidepressants or exercise. For the case series, large effect sizes pre–post within the group were found at 1 week ($g = 1.79$) with a weighted mean response rate of 61.6%, suggesting that triple chronotherapy appears promising for the treatment of depressive disorder in in-patients. On the basis of these results, the aim of the current study was to conduct a feasibility and pilot RCT of triple chronotherapy for unipolar depression in out-patients.

Method

Trial design
A randomised parallel-group single-blind design comparing the addition of triple chronotherapy or a control sleep intervention to standard care was used. The protocol was first written in July 2017 and was modified in January 2018. Blue-light blocking glasses were added to the protocol before the trial began. No
previous piloting work was undertaken in 2017 and no changes were made to the protocol after the trial began.

Participants’ eligibility criteria

Inclusion criteria were an ICD-10 diagnosis of depressive episode (ICD-10 F32) or recurrent depressive disorder (F33); score of 8 or more on the 6-item Hamilton Rating Scale for Depression (HRSD-6) (also abbreviated as HAM-D6),1\(^1\) aged 18–65 years and capable of giving informed consent.

Exclusion criteria were a current diagnosis of seasonal affective disorder, anorexia nervosa or bulimia nervosa, obsessive–compulsive or related disorder, or post-traumatic stress disorder or emotionally unstable personality disorder considered to be the main problem; history of schizophrenia, schizoaffective disorder or bipolar disorder; severe cognitive impairment or organic brain disorder; history of stimulant or hallucinogenic misuse, alcohol or substance misuse or dependence in past 3 months; duration of depression more than 2 years; significant risk of suicide that requires hospital admission; blindness or visual impairment affecting both eyes (which diminishes vision); history of epilepsy; as this may lower seizure threshold through sleep deprivation; untreated sleep disorder such as obstructive sleep apnoea or narcolepsy; use of photo-sensitising drugs; current night-shift work; and non-English speaker.

Interventions

All eligible participants were randomised to receive either triple chronotherapy or a control sleep intervention.

Triple chronotherapy

The timetable for triple chronotherapy is shown graphically in supplementary Fig 1, available online at http://dx.doi.org/10.1192/bjo.2021.1044. It consisted of the following.

(a) Total sleep deprivation for 36 hours. On day 1 (usually a Friday), participants, in small groups, were helped to stay awake at night by an occupational therapist.

(b) Phase advance of sleep over 4 days. Phase advance began after the first night of sleep deprivation, when the participants left the hospital at about 08.00 h and were asked to go to bed earlier, at about 17.00 h, and to rise at about 01.00 h. Their sleep and wake up times were then shifted 2 h later on each of the following 3 days until they attained their usual bedtime again (about 23.00 h). During the period of phase advance, they were given amber (blue-blocking) glasses manufactured by SomniLight to wear 3 h before going to bed. This was designed to encourage release of melatonin and prevent a phase delay of sleep by evening light exposure.

(c) Daily bright-light therapy was given on day 2 and continued for 6 months. The time of the light therapy was optimised in the morning in accordance with each patient’s chronotype and pattern of sleep, as determined by the Morningness–Eveningness Questionnaire.1\(^2\) A person’s chronotype is their internal circadian rhythm or body clock, which influences timing of the cycle of sleep and activity in a 24 h period. Participants were asked to sit about 1 foot (30 cm) away from a bright-light box that emitted 10 000 lux (Carex Day-Light Classic\(^\circ\)). It was positioned slightly above the head and pointing downwards at 45°. They were required to sit facing the light box (simply having a light box in the room does not ensure that the person receives adequate light intensity at eye level). The white light incorporates blue-green light in the 540 nm spectrum, which is known to suppress melatonin and to ‘phase advance’ its secretion if light is given in the morning. Patients were free to have breakfast, read or use a computer while facing the light. Treatment normally lasted 30 min and continued daily for 6 months. Further details on the practice of chronotherapy can be found in Wirz-Justice et al.1\(^3\)

Control intervention

As a control for the triple chronotherapy, participants were given psychoeducation and written information on sleep hygiene and getting a good night’s sleep, with the opportunity to ask questions. They were also given amber light (an amber lamp (SomniLight Amber Light, discontinued) manufactured by SomniLight) daily for 1 week in the morning. The rationale was that amber light (peaking at 592 nm wavelength and 300 lux at 30 cm) does not suppress melatonin secretion or have a significant impact on the melatonin phase and it was given as a control for the bright-light therapy. Participants had the same instructions as for the bright-light therapy and optimisation of timing for the light in the morning.

Outcomes

The primary outcome was the number of participants recruited per month and adherence to the protocol, with 1 week as the primary end-point. The secondary outcome measures were the masked (‘blind’) observer-rated 6-item Hamilton Rating Scale for Depression (HRSD-6)\(^1\(^1\)\) (total range 0–22: scores 0–4, no or minimal depression; 5–8, mild; 9–10, moderate; 11–13, severe; >13, very severe); the observer-rated Clinical Global Impression – Improvement scale;\(^1\(^4\)\) the Quick Inventory of Depressive Symptomatology – self-report version;\(^1\(^5\)\) the Brief Penn State Worry Questionnaire (5-item) and the Ruminative Response Scale (5-item); the Pittsburgh Sleep Quality Index;\(^1\(^7\)\) and the EuroQol 5D.\(^1\(^8\)\) All measures were done at baseline and at 1, 2, 3, 4 and 26 weeks post-randomisation. Participants were given a commercial tracker (Fitbit\(^\circ\)) for 1 week to collect activity and sleep data.

Sample size

This was a feasibility and pilot study and therefore we wished to evaluate feasibility parameters such as the rate of recruitment, loss to follow-up and treatment adherence and to estimate the variability of the outcome. Thirty people equally randomised to each group completing a study is usually considered adequate for a feasibility and pilot study\(^1\(^9\)\) and allows informative 95% confidence intervals (CIs) to be estimated on feasibility parameters. Of the 173 individuals approached, 82 participants were randomised for 60 people to complete the study.

Randomisation

The method of randomisation consisted of simple randomisation based on a constant allocation ratio of 1:1. It was stratified according to the season.

Randomisation was conducted by an independent research worker via the King’s Clinical Trials Unit (which is registered with the UK Clinical Research Collaboration) using a web-based
random sequence generator system. The same research worker concealed the sequence until he assigned participants to the interventions.

Sources of bias
Participants recorded the credibility of the treatment and expectancy of benefit after they were allocated to a group.20 The use of antidepressant medication and whether they were receiving any counselling or psychotherapy was recorded at baseline.

Masking
The research associate administering the observer-rated assessments was masked to group assignment. Participants were reminded at each time point the importance of not disclosing under any circumstances the treatment to which they were assigned. Participants were enrolled, screened and assessed by a different research worker from the one who organised the interventions for all participants. The research workers each had separate recording systems and different passwords to maintain masking.

Analysis
Feasibility outcomes were presented as frequencies and proportions. We explored outcomes and our analysis presents means, 95% CI and effect sizes for the two intervention groups by time (at 1, 2, 4, 8 and 26 weeks). We conducted a linear mixed model analysis to determine the estimated means and standard errors of outcomes using the maximum likelihood estimation. The model uses all available data. If data are missing at random, model parameters will be unbiased. We also calculated a standardised effect size and confidence interval between the groups from all available data at each time point by dividing the estimated mean difference (from the mixed model) by the standard deviation of the measure at baseline. As per the rule of thumb for Cohen’s $d$, standardised effect sizes were described as small ($ES = 0.2$), medium ($ES = 0.5$) or large ($ES = 0.8$) and effect sizes were presented with 95% CI. Where hypothesis tests were carried out, the criterion for significance was $P < 0.05$ and all tests were two-tailed. Data on all participants who started treatment were analysed according to their randomised groups (modified intention to treat). Participants who were randomised but did not commence treatment were included in a consideration of drivers of pre-treatment drop-out.

Ethics
Written informed consent was obtained from all participants. The authors assert that all procedures contributing to this work complied with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants/patients were approved by the London Bromley Research Ethics Committee (reference 17/LO/1567). The trial is registered with Clinicaltrials.gov (NCT03405493) and the ISRCTN registry (ISRCTN17706836).

Recruitment
Participants were recruited between the 5 February 2018 and 22 March 2019. The final follow-up was on 13 September 2019. Inclusion rate into the study was less than 50% (screening 173 individuals for 82 to be randomised).

Baseline data
Participant demographics are shown in Table 1. Of the 82 participants, 44 were not taking any medication; 38 were taking an antidepressant or mood stabiliser (citalopram, $n = 13$; escitalopram, $n = 5$; fluoxetine, $n = 2$; mirtazapine, $n = 1$; paroxetine, $n = 1$; sertraline, $n = 14$; quetiapine, $n = 1$; and lamotrigine, $n = 1$); 34 participants were receiving psychotherapy. There were no significant differences between the groups at baseline, including HRSD-6 scores.

Pre-treatment drop-out
Eighty-two participants were recruited and randomised for this study and 23.2% ($n = 19$) did not commence either intervention after randomisation. The number who dropped out before the treatments commenced was $n = 13$ for the triple chronotherapy group and $n = 6$ for the control group (Fig. 1). Once participants had received the intervention the retention at 6-month follow-up was adequate in both the triple chronotherapy (77%, $n = 20/26$) and the control group (73%, $n = 27/37$). There were no significant differences between those who had at least 1 week of treatment and those who dropped out after randomisation in the frequency of taking antidepressant medication, receiving a psychological therapy, relationship status or employment status. There was a difference in baseline HRSD-6 scores, with those who dropped out (HRSD-6 score: mean 10.9, s.d. = 1.84) being significantly less depressed than completers (mean 11.89, s.d. = 1.66, $t = -2.58$, $P < 0.05$). There was also a significant difference in age ($t = -2.5$, $P < 0.05$), where those who dropped out were younger than those who received any treatment (mean 31.9 years, s.d. = 13.0 and mean 40.4 years, s.d. = 12.9 respectively), and gender ($\chi^2(82) = 5.79$, $P < 0.05$), as those who dropped out were biased towards more females ($n = 15$) than males ($n = 4$) in comparison with those who received any treatment ($n = 30$ females; $n = 33$ males). Of the 82 randomised, 26 received triple chronotherapy and 37 received the sleep control for at least 1 week.

Missing outcome data for treatment starters
Frequency of missing data for HRSD-6 ratings was low in both groups up to week 8 (see supplementary Table 4), at 14% overall. At week 26, almost a quarter of participants had missing ratings ($n = 6$, 23%). Logistic regression with missingness as outcome showed no significant differences in rates of missingness between groups at weeks 8 and 26.

Adherence (primary outcome)
All participants in the triple chronotherapy group adhered to the sleep deprivation. They were supervised by an occupational therapist to stay up at night without napping. In terms of acceptability of the intervention, adherence to triple chronotherapy was estimated by examining sleep diaries, which were submitted by 18 of the 25 participants (72%) for the first week after sleep deprivation. None reported going to sleep before 17.00 on the first day and only 2 participants out of the 18 (11.1%) were judged to be not adhering to the plan of phase advance. For the remainder in the 18, the planned time of sleep onset was occasionally advanced or delayed by up to 1 h against the plan. We collected 25 diaries from the 37 participants.
Assessed for eligibility (n = 173)
  Excluded (n = 91)
    • Not meeting inclusion criteria (n = 47)
    • Declined to participate (n = 21)
    • Other reasons (n = 23)
  Not meeting inclusion criteria (n = 47)
  Declined to participate (n = 21)
  Other reasons (n = 23)
Randomised (n = 82)
  Allocated to triple chronotherapy (n = 39)
    • Received allocated intervention (n = 26)
    • Did not receive allocated intervention (n = 13)
      - No further communication (n = 5)
      - Difficulty with time commitments (n = 1)
      - Life circumstances (n = 4)
      - No longer eligible (n = 2)
      - Withdraw-no reason provided (n = 1)
  Allocated to control (n = 43)
    • Received allocated intervention (n = 37)
    • Did not receive allocated intervention (n = 6)
      - No further communication (n = 4)
      - Withdrew due to perceived ineffectiveness of treatment (n = 1)
      - Recovery of symptoms (n = 1)
Allocation
Received allocated intervention (n = 25)
  Lost to follow-up (n = 1)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 37)
  Lost to follow-up (n = 0)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 25)
  Lost to follow-up (n = 0)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 37)
  Lost to follow-up (n = 0)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 25)
  Lost to follow-up (n = 1)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 37)
  Lost to follow-up (n = 0)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 25)
  Lost to follow-up (n = 0)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 37)
  Lost to follow-up (n = 4)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 24)
  Lost to follow-up (n = 1)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 33)
  Lost to follow-up (n = 2)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 23)
  Lost to follow-up (n = 3)
  Discontinued intervention (n = 0)
  Received allocated intervention (n = 31)
  Lost to follow-up (n = 3)
  Withdraw from study (n = 1)
Analysis
  Analysed (n = 39)
    • Excluded from analysis (n = 0)
  Analysed (n = 43)
    • Excluded from analysis (n = 0)
in the control group (67.7%) for the same period: 15 out of the 25 (60%) got up fairly consistently by 08.00 h in accordance with the sleep hygiene programme.

**Secondary outcomes**

Table 2 gives the results of the linear mixed model analysis of secondary outcomes. Standardised effect sizes showed moderate to large differences between groups from week 1 onwards, and effect sizes were above 1 for weeks 8 and 26 (and statistically significant at weeks 1, 8 and 26). The raw scores are provided in supplementary Table 3. This was replicated at the same time points for the self-report measure on depression (Quick Inventory of Depressive Symptomatology, QIDS-SR). Effect sizes for the differences between two groups were more modest for the Penn State Worry Questionnaire (PSWQ) until week 8 and the effect size for the Ruminative Response Scale (RRS) and EuroQoL 5D (EQ-5D) were only small until week 26, at which point the large difference was statistically significant.

Response was defined as a 50% reduction of symptoms on the HRSD-6. In an intention-to-treat analysis (Table 3), the proportion of responders was 33.3% in the triple chronotherapy group, compared with 16.2% in the control group. This stayed relatively steady up to week 26, with 35.9% responders in the triple chronotherapy group, compared with 13.9% in the control group. Of note is that 9/20 (45%) achieved a response in the first week in the triple chronotherapy group and this was maintained from week 1 onwards (supplementary Table 2). A further 6 out of 20 (30%) achieved a response from weeks 2 to 8 (when receiving bright-light therapy).

Supplementary Table 1 shows the odds ratio for the Clinical Global Impression–Improvement scale (CGI-I), which, like the HRSD-6 and QIDS-SR, found a significant difference at weeks 1, 8 and 26. There was a large effect size of Cohen’s $d = 0.8$ on the HRSD-6 at week 1, increasing to $d = 1.30$ at week 26 in a per protocol analysis (supplementary Table 3). The effect size was comparatively smaller for the QIDS-SR ($d = 1.0$ at week 26) and the PSWQ ($d = 1.06$) and slightly smaller for the RRS ($d = 0.86$), PSQI ($d = 0.54$) and EQ-5D ($d = 0.87$).

Information regarding other treatments received were collected at 26-week follow-up. There was no significant difference between groups for the number who had been receiving a psychological therapy (5/24, 21%) in the triple chronotherapy group and in the control group (4/34, 12%; $\chi^2(57) = 0.36$). There was also no significant difference between the number taking antidepressant medication (9/24, 37%) in the triple chronotherapy group and the sleep control group (8/34, 24%; $\chi^2(57) = 0.86$).

There were no reported side-effects from either intervention.

**Systematic measures of bias**

There was no difference between the groups in the proportion receiving either a psychological therapy or taking medication (Table 1). We calculated fluoxetine equivalents$^{21}$ and found no
We were able to recruit a sufficient number of participants who adhered to the treatment and therefore demonstrated the feasibility of delivering triple chronotherapy in a trial involving out-patients with depression. The potential benefits of triple chronotherapy in ensuring a rapid improvement in mood would be to prevent in-patient admission and the risk of suicide or reduce the use of other resources. A strength of the study was that there was a strong control group. Both treatments were rated as equally credible and had the same expectation for benefit ($t = 0.14$, $P = 0.89$). There was no significant difference between the groups in the rating of the credibility of the treatment ($t = -0.739$, $P = 0.23$) and the expectation for benefit ($t = 0.44$, $P = 0.33$).

### Table 2: Estimated mean group differences across time by intention-to-treat analysis

|                  | Week 1     | Week 2     | Week 4     | Week 8     | Week 26    |
|------------------|------------|------------|------------|------------|------------|
| **HRSD-6 (depression)** |            |            |            |            |            |
| Mean (95% CI)    | 1.87 (0.3 to 3.44) | 1.47 (−0.09 to 3.03) | 1.44 (−0.14 to 3.02) | 3.4 (1.8 to 4.99) | 4.01 (2.08 to 5.94) |
| t (d.f.)         | 2.3 (110.7) | 1.9 (114.9) | 1.8 (128.5) | 0.021 | 0.067 |
| P                | 0.093 | 0.17 | 0.045 | 0.039 | 0.14 |
| **QIDS-SR (depression)** |            |            |            |            |            |
| Mean (95% CI)    | 3.02 (0.78 to 5.26) | 1.18 (−1.05 to 3.41) | 1.9 (−0.33 to 4.12) | 3.73 (1.51 to 5.95) | 4.47 (1.93 to 7) |
| t (d.f.)         | 2.6 (105.8) | 1 (110.8) | 1.7 (119.8) | 0.030 | 0.303 |
| P                | 0.010 | 0.73 | 0.04 | 0.026 | 0.001 |
| **Brief PSWQ (worry)** |            |            |            |            |            |
| Mean (95% CI)    | 1.43 (−0.36 to 3.22) | 1.17 (−0.61 to 2.95) | 1.25 (−0.52 to 3.01) | 2.27 (0.51 to 4.03) | 2.88 (0.69 to 5.07) |
| t (d.f.)         | 1.6 (88.6) | 1.3 (92.1) | 1.4 (97.3) | 0.29 | 0.12 |
| P                | 0.120 | 0.26 | 0.26 | 0.28 | 0.13 |
| **Brief RRS (ruminatio)** |            |            |            |            |            |
| Mean (95% CI)    | 1.44 (0.01 to 2.87) | 0.63 (−0.79 to 2.06) | 0.49 (−0.93 to 1.91) | 0.71 (−0.72 to 2.14) | 2.25 (0.43 to 4.08) |
| t (d.f.)         | 2.92 (8.8) | 0.9 (97.1) | 0.7 (103.7) | 0.20 | 0.04 |
| P                | 0.051 | 0.33 | 0.04 | 0.28 | 0.04 |
| **PSQI (sleep)** |            |            |            |            |            |
| Mean (95% CI)    | 1.38 (−0.21 to 2.97) | 2.2 (0.61 to 3.78) | 2.36 (0.78 to 3.93) | 2.35 (0.77 to 3.93) | 1.92 (0.09 to 3.75) |
| t (d.f.)         | 1.7 (83.1) | 2.7 (88.3) | 2.9 (93.4) | 0.13 | 0.008 |
| P                | 0.095 | 0.18 | 0.04 | 0.28 | 0.04 |
| **SES (95% CI)** |            |            |            |            |            |
| Mean (95% CI)    | −3.87 (−11.81 to 4.07) | −6.74 (−14.65 to 1.17) | −3.9 (−11.77 to 3.96) | −4.97 (−12.83 to 2.9) | −14.03 (−23.34 to −4.72) |
| t (d.f.)         | −1 (145) | −1 (154.8) | −1 (171.3) | 0.341 | 0.097 |
| P                | 0.341 | 0.29 | 0.04 | 0.28 | 0.04 |

**HRSD-6, 6-item Hamilton Rating Scale for Depression; QIDS-SR, Quick Inventory of Depressive Symptomatology self-report version; PSQI, Penn State Worry Questionnaire; RRS, Ruminative Response Scale; PSWQ, Pittsburgh Sleep Quality Index; SES, standardised effect size; EQ-SD, EuroQOL 5D.**

### Table 3: Percentage achieving response by intention to treat analysis on the HRSD-6

|                  | Triple chronotherapy | Control group |
|------------------|----------------------|---------------|
| n/N              | 13/39               | 7/43          |
| %                | 33.3                 | 16.2          |
| **Week 1**       |                      |               |
| n/N              | 13/39               | 6/43          |
| %                | 33.3                 | 13.9          |
| **Week 2**       |                      |               |
| n/N              | 13/39               | 10/43         |
| %                | 33.3                 | 23.3          |
| **Week 4**       |                      |               |
| n/N              | 13/39               | 4/43          |
| %                | 33.3                 | 9.3           |
| **Week 8**       |                      |               |
| n/N              | 14/39               | 6/43          |
| %                | 35.9                 | 13.9          |
| **Week 26**      |                      |               |

**HRSD-6, 6-item Hamilton Rating Scale for Depression.**

### Table 4: Percentage achieving response by per protocol analysis on the HRSD-6

|                  | Triple chronotherapy | Control group |
|------------------|----------------------|---------------|
| n/N              | 13/25               | 7/37          |
| %                | 52                   | 18            |
| **Week 1**       |                      |               |
| n/N              | 13/25               | 6/37          |
| %                | 52                   | 16            |
| **Week 2**       |                      |               |
| n/N              | 13/24               | 10/33         |
| %                | 54                   | 30            |
| **Week 4**       |                      |               |
| n/N              | 13/23               | 4/31          |
| %                | 57                   | 13            |
| **Week 8**       |                      |               |
| n/N              | 14/20               | 6/27          |
| %                | 70                   | 22            |
| **Week 26**      |                      |               |

**HRSD-6, 6-item Hamilton Rating Scale for Depression.**

Discussion

significant difference in mean fluoxetine equivalent dose between the groups ($t = 0.43$, $P = 0.33$). There was no significant difference between the groups in the rating of the credibility of the treatment ($t = -0.739$, $P = 0.23$) and the expectation for benefit ($t = 0.44$, $P = 0.33$).
when they have confirmed that they can comply with the trial protocol (for example sleep deprivation on a planned day) and increasing the frequency of delivering the treatment.

The treatment, when received, was acceptable and feasible. Participants were able to adhere to the sleep deprivation with the support of the occupational therapist and did not nap during the first night. Only 2 out of the 18 (11.1%) in the triple chronotherapy group who kept sleep diaries were not able to adhere to the plan of phase advance after sleep deprivation. It was encouraging that both treatments were rated as equally credible and had the same expectation for change. Our study was a feasibility and pilot study and therefore the reported secondary outcomes are exploratory. Our findings are consistent with 4 small RCTs and 12 case series;10 45% achieved response and an effect size of $d = 0.8$ after 1 week for triple chronotherapy compared with a control treatment. Triple chronotherapy has significant promise as an effective and rapid treatment for depression and that can be delivered to outpatients.

All the other secondary outcomes, including the self-report scale for depression, were in the same direction. Sleep did not significantly improve until week 2. Five out of twenty (25%) in the triple chronotherapy group achieved response from week 2 to 8, which suggests that the bright-light therapy may have an independent beneficial effect in 25% of participants. Martiny et al12 also found that bright-light therapy maintained response in early responders to sleep deprivation. Previous research has shown that bright-light therapy can be beneficial in non-seasonal depression. Previous meta-analyses of studies of bright-light therapy have been difficult to interpret because of the heterogeneity, with many studies conducted over 1–2 weeks.5,24 We are not able from this small study to determine moderators or mechanisms for change. Ruminatio is often associated with chronic depression.25 Outcomes on the Ruminative Response Scale were not significant until week 26, suggesting that triple chronotherapy may be less effective for people who are very self-critical and are ruminators.

Limitations

This was primarily a feasibility and pilot study to determine adherence and rate of recruitment. Caution should therefore be applied, as any RCT with small numbers is always at risk of overestimating effect size and rate of response. However, our results are consistent with previous studies and meta-analysis in in-patients. To explore the secondary outcomes the end-point was the end of week 1. Thus, we wanted to ensure that both groups had a treatment in the first week that had an equal credibility and expectation rating (which we achieved). The continuation phase suggests that bright-light therapy may have added benefits. However, after week 1 the control group only had advice on sleep hygiene and treatment as usual. Future studies should control for the continuation phase. We did not conduct a systematic enquiry for possible side-effects, but none was reported. Future research is required to document formally the severity of any side-effects and their duration.

We did not explore predictors of response because of the small sample size. There are areas for improvement in a larger trial and one can improve the rates of drop-out after randomisation by better logistics in starting the treatment. We attempted to collect objective data on sleep and activity but were let down by the accuracy of the tracker. This is a recognised limitation of commercial trackers.26 Our participants may have exaggerated their compliance with advancing the timing of their sleep or with sleep hygiene. We did not collect any measure of light therapy adherence during the 6 months. However, there are newer actigraphs that also have a light meter and in future research, it should be possible to collect information on level of exposure to light during the treatment protocol.

This was a clinical effectiveness study and so we included participants typical of a primary care service who were taking antidepressants or receiving psychotherapy, which increases the heterogeneity of treatments received. However, there was no significant difference between the groups in terms of treatments received and importantly the credibility of the interventions and expectations. Restricting the study to participants who were not receiving any current active treatment would have meant a significantly slower recruitment rate.

Generalisability

Our participants were out-patients mainly recruited from primary care and were not a population with severe or treatment-refractory depression. Thus, the ability to recruit and for participants to adhere to the treatment cannot be generalised to out-patients in secondary or tertiary care. Future work may also consider whether recruitment should include people from different demographic areas to ensure that findings are generalisable to a wider population.

Interpretation

A larger definitive RCT to evaluate the clinical and cost-effectiveness of triple chronotherapy in the out-patient treatment of depression is now required.

Supplementary material

Supplementary material is available online at https://doi.org/10.1192/bjp.2021.1044.

Data availability

The data that support the findings of this study are available on request from the corresponding author.

Acknowledgements

This study represents independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. We thank all study participants for their time and Brett Hayes for his assistance in data collection.

Author contributions

D.V. contributed to the conceptualisation, methodology, writing original draft and funding acquisition. M.S. contributed to the conceptualisation, methodology, writing — review and editing and funding acquisition. C.H. contributed to the conceptualisation, methodology, writing — review and editing, validation and project administration. A.P. contributed to the formal analysis, validation and writing — review and editing. S.M. contributed to the conceptualisation, methodology and writing — review and editing. J.H.V. contributed to the formal analysis, methodology and writing — review and editing. A.H.Y. contributed to the conceptualisation, methodology, supervision, writing — review and editing and funding acquisition.

Funding

This study was supported by the MRC Confidence in Concept award to King’s College London (Grant ref: MC PC 16048).
Declaration of interest

A.Y. is a member of the bjo.2021.1044.10

References

1 Gibertini M, Nairns KR, Whitaker JA. Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design. Int Clin Psychopharmacol 2012; 27: 100–6.

2 Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–66.

3 Cuijpers P, Karyotaki E, Reijnders M, Huibers MJH. Who benefits from psychotherapies for adult depression? A meta-analytic update of the evidence. Cogn Behav Ther 2018; 47: 91–106.

4 Pflug B, Tolle R. Disturbance of the 24-hour rhythm in endogenous depression and the treatment of endogenous depression by sleep deprivation. Int Pharmacopsychiatry 1971; 6: 187–96.

5 Boland EM, Rao H, Dinges DF, Smith RV, Goel N, Detre JA, et al. Meta-analysis of the antidepressant effects of acute sleep deprivation. J Clin Psychiatry 2017; 78: e1020–34.

6 Martiny K, Retsgaard E, Lund V, Lunde M, Sorensen L, Thouggaard B, et al. The day-to-day acute effect of wake therapy in patients with major depression using the HAM-D-6 as primary outcome measure: results from a randomised controlled trial. PLoS One 2013; 8(6): e67264.

7 Wirz-Justice A, Benedetti F. Perspectives in affective disorders: clocks and sleep. Eur J Neurosci 2020; 51: 346–65.

8 Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health. Transl Psychiatry 2020; 10(1): 28.

9 D’Agostino A, Ferrara P, Terzoni S, Ostinelli EG, Carrara C, Prunas C, et al. Efficacy of triple chronotherapy in unipolar and bipolar depression: a systematic review of the available evidence. J Affect Disord 2020; 276: 297–304.

10 Humphson C, Benedetti F, Serfaty M, Markham S, Hodossi J, Young AH, et al. Chronotherapy for the rapid treatment of depression: a meta-analysis. J Affect Disord 2020; 261: 91–102.

11 Timmerby N, Andersen JH, Sandegaard S, Østergaard SD, Bech P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D-6). Psychother Psychosem 2017; 86: 141–9.

12 Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 1976; 4: 97–110.

13 Wirz-Justice A, Benedetti F, Terman M. Chronotherapeutics for Affective Disorders: A Clinician’s Manual for Light and Wake Therapy. Karger, 2013.

14 Guy W. The ECDEU Assessment Manual for Psychopharmacology – Revised. US Department of Health, Education, and Welfare, 1976.

15 Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73–82.

16 Topper M, Emmelkamp PM, Watkins E, Ehrring T. Development and assessment of brief versions of the Penn State Worry Questionnaire and the Rumination Response Scale. Br J Clin Psychol 2014; 53: 402–21.

17 Buyse D, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193–213.

18 EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199–208.

19 Browne RH. On the use of a pilot sample for sample size determination. Stat Med 1995; 14: 1933–40.

20 Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry 2000; 31: 73–86.

21 Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, et al. Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials. J Affect Disord 2015; 180: 179–84.

22 Martiny K, Retsgaard E, Lund V, Lunde M, Thouggaard B, Lindberg L, et al. Maintained superiority of chronotherapeutics vs. exercise in a 20-week randomized follow-up trial in major depression. Acta Psychiatr Scand 2015; 131: 446–57.

23 Gottlieb JF, Benedetti F, Geoffroy PA, Henriksson TEG, Lam RW, Murray G, et al. The chronotherapeutic treatment of bipolar disorders: a systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. Bipolar Disord 2019; 21: 741–73.

24 Penders TM, Stanciu CN, Schoemann AM, Ninan PT, Bloch R, Sadeh SA. Bright light therapy as augmentation of pharmacotherapy for treatment of depression: a systematic review and meta-analysis. Prim Care Companion CNS Disord 2016, 18(5).

25 Watkins E, Mullan E, Wngrove J, Rimes K, Steiner H, Bathurst N, et al. Rumination-focused cognitive-behavioural therapy for residual depression: Phase II randomised controlled trial. Br J Psychiatry 2011; 199: 317–22.

26 Feehan LM, Geldman J, Sayre EC, Park C, Ezzat AM, Yoo JY, et al. Accuracy of photometry of short-wavelength light exposure in human circadian rhythms. In: Karger, 2013.

27 Watkins E, Mullan E, Wngrove J, Rimes K, Steiner H, Bathurst N, et al. Rumination-focused cognitive-behavioural therapy for residual depression: Phase II randomised controlled trial. Br J Psychiatry 2011; 199: 317–22.

28 Feehan LM, Geldman J, Sayre EC, Park C, Ezzat AM, Yoo JY, et al. Accuracy of photometry of short-wavelength light exposure in human circadian rhythms. In: Karger, 2013.